Drug Trial Radar · NCT01703702
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Last checked: Nov 19, 2026Latest source record: Aug 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
641
Actual
Start
Oct 2012
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- Avid RadiopharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Oct 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.
Conditions
- Alzheimer's Disease
Interventions
florbetapir (18F)Drug
Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical and Diagnostic Change in Patient ManagementTime frame: Baseline and 3 months
- Change in ADAS-Cog 11 Total ScoreTime frame: Baseline and 12 months
Locations
57 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Scottsdale, Arizona
Research Site
Sun City, Arizona
Research Site
Clearwater, Florida
Research Site
Miami Beach, Florida
Research Site
Orlando, Florida
Research Site
West Palm Beach, Florida
Research Site
Shreveport, Louisiana
Research Site
Boston, Massachusetts
Research Site
Chestnut Hill, Massachusetts
Research Site
Quincy, Massachusetts
Research Site
Las Vegas, Nevada
Research Site
Las Vegas, Nevada
Research Site
Patchogue, New York
Research Site
Durham, North Carolina
Research Site
Greensboro, North Carolina
Research Site
Providence, Rhode Island
Research Site
Providence, Rhode Island
Research Site
Salt Lake City, Utah
Research Site
Bennington, Vermont
Research Site
Amiens, France
Research Site
Bordeaux, France
Research Site
Bron, France
Research Site
Dijon, France
Research Site
Lille, France
Research Site
Marseille, France
Research Site
Montpellier, France
Research Site
Nancy, France
Research Site
Nantes, France
Research Site
Nice, France
Research Site
Paris, France
Research Site
Pessac, France
Research Site
Reims, France
Research Site
Rouen, France
Research Site
Strasbourg, France
Research Site
Toulouse, France
Research Site
Tours, France
Research Site
Villeurbanne, France
Research Site
Bergamo, Italy
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.